The annual ASCO Gastrointestinal (GI) Cancers Symposium is the place for medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists, nurses, patients, patient advocates and others to unite in their efforts to improve the multidisciplinary approach toward the optimal care for GI cancer patients.
… And meet colleagues from all over the world.
Top 5 reasons why I love going to conferences! 1) seeing and interacting with my peers who treat the same disease as I do. 2) meeting new faces who have a passion about oncology as I do 3) seeing all of the latest research that I can bring to my patients! #GI19
— Ravi R (@medoncdoc) January 17, 2019
Remarkable study in @ASCO #GI19 evaluating Pembrolizumab in 2nd line esophageal cancer. Note: only for PD-L1 > 10%. From my perspective, the most significant study at #GI19. Practice-changing. #EndCancer #cancer #CancerResearch pic.twitter.com/U4I1DvEpd8
— Alexandre Jacome (@AJacomeMD) January 17, 2019
Triplets are so 2018!
— Mark Lewis (@marklewismd) January 17, 2019
CAPOX+Herceptin+pembro had an 87% ORR and 100% DCR (median PFS ~ 11 months) in a study by Dr Janjigian & MSKCC colleagues of her2-positive gastric cancer #GI19 pic.twitter.com/QA4R5yPFY0
The meeting brought forth many advancements in treatment for EG cancer…
Honored to write an Expert Editorial for @asco with @skopetz at @MDAndersonNews . ctDNA is an important technology for understanding risk for recurrence in resected colon cancer and we are committed to moving the bar forward for improving outcomes in #crcsm . #GI19 @TGeorgeMD pic.twitter.com/pWOGunBzvo
— Van Morris, MD (@VanMorrisMD) January 19, 2019
Colon cancer…
Honored to write an Expert Editorial for @asco with @skopetz at @MDAndersonNews . ctDNA is an important technology for understanding risk for recurrence in resected colon cancer and we are committed to moving the bar forward for improving outcomes in #crcsm . #GI19 @TGeorgeMD pic.twitter.com/pWOGunBzvo
— Van Morris, MD (@VanMorrisMD) January 19, 2019
Biliary tract cancer…
Very promissing regimen! Ph2 ROAR : Dabrafenib + Trametinib in BRAF V600 mut refractory Billiary Tract Cancer (80% received > 2 lines) showed ORR 36% & 66% 6mo DoR. The estimated mOS 11.7mo. #GI19 pic.twitter.com/uQEfy5i0Dn
— Ricardo Carvalho (@rcarvalhoonco) January 18, 2019
Pancreatic cancer…
#GI19 This is why it’s important to do sequencing in pancreatic cancer.... pic.twitter.com/jB2QDFDjJg
— Ravi R (@medoncdoc) January 18, 2019
PRODIGE study in pancreatic cancer truly a game changer #GI19 pic.twitter.com/ol7eYVgdZL
— Grant Williams (@GrantWilliamsMD) January 18, 2019
#GI19 You don’t have to be a PRODIGE to see that this #data is #gamechanging and gives hope to patients with #pancreaticcancer as well as to their #doctors @ASCO @letswinpc pic.twitter.com/GfNi5TjwQi
— Dr. Allyson Ocean (@drallysonocean) January 18, 2019
Randomized trial from Japan shows higher survival with preop chemo vs. upfront surgery for *resectable* pancreatic cancer. The data for neoadjuvant therapy for pancreatic cancer keeps getting stronger. #GI19 pic.twitter.com/xuUV0W7hmF
— Prajnan Das, MD, MS, MPH (@PrajnanDasMD) January 18, 2019
Neuroendocrine tumors…
A veritable revolution in the management of neuroendocrine tumors has occurred during this decade #gi19
— Mark Lewis (@marklewismd) January 18, 2019
cc:@CureNETs @NANETS1 @RonnyAllan1 @Globeseek @AMEN_SUPPORT @CarcinoidNETs pic.twitter.com/svnz9ndjPv
Colorectal cancer…
Mentor, friend, colleague @TGeorgeMD giving us a state of the science for total neoadjuvant chemotherapy in #colorectalcancer . Thom is a true champion for patients. @UFHealthCancer #GI19 #GoGators pic.twitter.com/5fWPKqXdta
— Jason Starr (@drjasonstarr) January 19, 2019
#GI19 @ASCO results of COLOPEC prophylactic trial shows no benefit of adjuvant HIPEC for high risk CRC. Now 3/3 negative studies of HIPEC in colorectal cancer. Where to go from here? pic.twitter.com/r0ZkXA4une
— George J Chang (@ColonCancerDoc) January 19, 2019
My 10yr selfie of #colorectal #cancer management. We're working on the next 10yrs today! #clinicaltrials #GI19 @ASCO; Credit to @ajf324MD pic.twitter.com/8cmkq72Il3
— Thomas George MD (@TGeorgeMD) January 19, 2019
Of course, there was an emphasis on the value of precision medicine.
Precision medicine for #cholangiocarcinoma is real. Hope and Progress for our patients. #GI19 highlights this PM! pic.twitter.com/ZMdem8OQx8
— KModyMD (@kmody29) January 19, 2019
Great day #GI19 with excellent talks from @DrGarciaAguilar @TGeorgeMD @skopetz & many others - especially liked @skopetz thoughts on continued pursuit of useful biomarkers and platforms in pts with colorectal cancer & engagement of pts who know their biomarker profile @FightCRC pic.twitter.com/rT8oBNVPkC
— Josh Smith, MD, PhD, FACS (@smithj10Smad4) January 19, 2019
Overall, it was a great meeting for all those who attended.
Thank you 🙏 @ASCO #GI19 for giving our students and trainees an opportunity and a platform to present. It was refreshing to see so not just fellows and postdocs, but also residents, research trainees and medical students presenting important research findings. 👩🎓👨🎓#MedEd
— Pashtoon Kasi MD, MS (@pashtoonkasi) January 20, 2019
That’s a wrap for ASCO GI Cancers Symposium 2019!
Illustration by Jennifer Bogartz
